Grace Therapeutics, Inc.
GRCE
Rank in Stocks
#24815
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Share Price
$1.87
Last synced: 2026-11-09
Market Cap
$30.35M
Change (1 day)
0.81%
Change (1 year)
-37.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Grace Therapeutics, Inc. (GRCE)
Category
Healthcare
EPS for Grace Therapeutics, Inc. (GRCE)
EPS as of June 2026 TTM: $-1.26
According to Grace Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.26. At the end of 2025 the company had an EPS of $-1.13, an increase over its 2024 EPS of $-1.83.
EPS history for Grace Therapeutics, Inc. from 2009 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.26 | 11.50% |
| 2025 | $-1.13 | -38.25% |
| 2024 | $-1.83 | -76.30% |
| 2023 | $-7.72 | 282.18% |
| 2022 | $-2.02 | -79.84% |
| 2021 | $-10.02 | -50.98% |
| 2020 | $-20.44 | -41.42% |
| 2019 | $-34.89 | -24.13% |
| 2018 | $-45.99 | 34.11% |
| 2017 | $-34.29 | 57.42% |
| 2016 | $-21.78 | 155.59% |
| 2015 | $-8.52 | -86.75% |
| 2014 | $-64.33 | 52.59% |
| 2013 | $-42.16 | -12.79% |
| 2012 | $-48.34 | 66.20% |
| 2011 | $-29.09 | -8.85% |
| 2010 | $-31.91 | 267.21% |
| 2009 | $-8.69 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,342.86% |
US
|
|
| $-7.07 | 461.11% |
US
|
|
| $-5.29 | 319.84% |
AU
|
|
| $12.88 | -1,122.23% |
BE
|
|
| $21.56 | -1,811.11% |
NL
|
Questions about Grace Therapeutics, Inc.'s earnings per share (EPS)
What is Grace Therapeutics, Inc.'s earnings per share (EPS)?
Grace Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.26, as of Jun 2026.
What was Grace Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Grace Therapeutics, Inc.'s earnings per share (EPS) was $-1.13, compared with $-1.83 in 2024.
How has Grace Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Grace Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.13) and lowest in 2020 ($-20.44).
How does Grace Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Grace Therapeutics, Inc.'s earnings per share (EPS) ($-1.26) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.